Guideline for Extended Release Oral Dosage Forms : Development, Evaluation, and Application of In Vitro/In Vivo Correlations |
Choi, Sun-Ok
(Drug Metabolism Team, Pharmacological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration)
Jeong, Sung-Hee (Drug Metabolism Team, Pharmacological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration) Um, So-Young (Drug Metabolism Team, Pharmacological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration) Jung, Seo-Jeong (Drug Metabolism Team, Pharmacological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration) Kim, Joo-Il (Drug Metabolism Team, Pharmacological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration) Kim, Ok-Hee (Drug Metabolism Team, Pharmacological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration) |
1 | R. S. Venkata, M. Uppoor, Regulatory perspectives on in vitro (dissolution)/in vivo(bioavailability) cerrelations, Journal of Controlled Release, 72, 127-132 (2001) DOI ScienceOn |
2 | 약사관계법령집 (2002) |
3 | 생불학적동등성시험기준, 식품의약품안전청고시 제 2005-31호, 2005. 6. 7 |
4 | Guidance for Industry: Waiver of in vivo Bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutical classification system. CDER, US FDA, August,2000 |
5 | Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluaion, and Application of In Vitro/In Vivo Correlations, US FDA (1997. 9.) |